We have shown that fosamprenavir binds to and inhibits pepsin and prevents pepsin-mediated laryngeal inflammation and damage in an in vivo model of LPR.  In support, patients taking HIV inhibitors have a significantly lower incidence of LPR compared to that reported for the general population.

LPR affects both children and adults, and the clinical spectrum is extensive.  Patients present with symptoms due to chronic laryngeal irritation, such as chronic cough, throat-clearing, post-nasal drip, dysphonia, globus, dysphagia, and dyspnea. Chronic LPR contributes to serious and life-threatening illness including airway stenosis, reactive airway disease, and laryngeal cancer.  LPR is estimated to affect more than 20% of the United States population and contribute to 10% visits to otolaryngologists.  Despite the high prevalence and disease burden, there’s no effective medical therapy for LPR.